Skip to main content

Table 2 Comparison of clinical and laboratory indicators between groups (median (lower quartile ~ upper quartile))

From: Correlation between the accumulation of skin glycosylation end products and the development of type 2 diabetic peripheral neuropathy

Variable

Grade 0 (n = 79)

Grade 1 (n = 199)

Grade 2 (n = 202)

Grade 3 (n = 80)

P

TG (mmol/L)

1.86 (1.13–2.93)c#

1.74 (1.13–2.71)e#

1.57 (1.07–2.40)

1.385 (0.92–2.12)

0.016*

HDL-C (mmol/L)

0.99 (0.82–1.16)

1.015 (0.84–1.16)

1.025 (0.87–1.22)

1.07 (0.93–1.32)

0.069

Cr (μmol/L)

59.1 (48.90–68.20)

63.25 (54.18–76.98)e#

61.95 (51.40–76.28)f##

73.5 (59.53–88.00)c##

0.000*

CysC (mg/L)

0.78 (0.67–0.89)a##

0.935 (0.77–1.21)e##

0.935 (0.80–1.18)bf##

1.09 (0.90–1.47)c##

0.000*

Hcy (μmol/L)

10.03 (7.21–12.47)c##

9.91 (7.81–13.26)

9.77 (8.22–12.88)f##

12.1 (9.55–15.79)e##

0.001*

ACR (mg/g)

12.35 (5.24–33.89)c##

14.46 (5.83–73.43)e#

16.63 (5.62–109.55)f#

51.21 (16.64–296.16)

0.005*

eGFR (ml/min)

109.59 (98.39–120.75)

97.9 (84.92–110.34)ae##

96 (80.98–108.94)bf##

84.84 (64.43–100.41)c##

0.000*

MAU (mg/L)

10.6 (5.34–25.60)c##

11.8 (5.15–62.00)e##

12.65 (4.36–51.03)f##

47.1 (9.39–239.50)

0.001*

α-MG (mg/L)

9.96 (55.25–15.73)c##

12.6 (5.30–25.80)

10.5 (5.01–24.10)f#

19.1 (7.79–34.30)

0.004*

Tf (mg/L)

2 (2.00–2.00)c##

2 (2.00–4.46)e#

2 (2.00–2.92)f##

2.12 (2.00–14.00)

0.000*

U-Ig G (mg/L)

3.75 (3.00–10.19)c##

5.36 (3.00–13.75)e#

4.36 (3.00–11.40)f##

9.15 (4.03–36.10)

0.001*

NEUT(109/L)

3.305 (2.70–4.08)

3.5 (2.70–4.34)

3.62 (2.67–4.52)

3.74 (2.80–4.60)

0.468

LY(109/L)

1.935 (1.45–2.54)

1.66 (1.25–2.17)a#

1.69 (1.25–2.04)b#

1.51 (1.26–1.84)c##

0.001*

NLR

1.64 (1.40–2.24)

2.01 (1.56–2.72)a#

2.13 (1.56–2.86)b##

2.415 (1.69–3.20)c##

0.000*

CRP (mg/L)

0.7 (0.50–1.80)

0.8 (0.50–2.58)

0.9 (0.50–2.60)

1 (0.60–7.60)c#

0.033*

HOMA-IR

1.86 (1.37–6.40)

1.82 (1.18–3.43)

2.005 (1.28–3.07)

0.93 (0.52–1.42)

0.257

PFG (mmol/L)

8.47 (6.38–11.35)

8.3 (6.41–10.17)

7.94 (5.94–10.53)

8.425 (6.25–11.53)

0.394

FINS (mIU/L)

6.78 (3.85–14.75)

7.005 (3.36–10.260

5.84 (3.93–8.59)

3.57 (2.29–4.46)

0.302

C-Peptide (nmol/L)

0.666 (0.45–0.83)

0.7275 (0.48–0.96)

0.646 (0.50–0.87)

0.554 (0.42–0.69)

0.158

2hC-peptide (nmol/L)

1.6 (1.22–2.47)

1.85 (1.29–2.53)

1.59 (1.10–2.10)

1.3 (0.79–2.06)

0.142

HbA1c(%)

9 (7.08–10.48)

8.35 (6.63–11.08)

7.8 (6.70–10.30)

7.35 (6.10–9.88)

0.103

  1. * The progressive significance level was 0.05. Significance of pared comparison after adjustment #P < 0.05; significance of paired comparison after adjustment ##P < 0.01. comparison of grades 0 and 1; comparison between grades 0 and 2; comparison of grades 0 and 3; comparison between levels 1 and 2; comparison between levels 1 and 3; comparison of levels 2 and 3